Rtw Investments Reduces $31M in uniQure N.V. ($QURE)

RTW Investments has reduced its stake in uniQure N.V. (NasdaqGS: QURE) by 1,125,106 shares, according to its latest Form 13F filing with the SEC. This cut represents a 30.3% decrease in its holdings, leaving RTW with 2,586,356 shares valued at approximately $71.3 million as of the reporting period.

What Changed in RTW Investments' uniQure Position

RTW Investments slashed its position in uniQure N.V. from 3,711,462 shares to 2,586,356 shares, a reduction of 1,125,106 shares or about 30.3%. The remaining stake is valued at around $71.3 million. This move reflects a significant reduction in their investment in the biotechnology company.

Other Institutional Activity in uniQure

Several other institutional investors also adjusted their positions in uniQure. Aberdeen Group PLC increased its holdings by 1,627,746 shares, ending with 5,306,386 shares valued at approximately $86.8 million. Two Sigma Investments, LP added 1,224,587 shares, bringing its total to 2,675,871 shares worth about $43.8 million. In contrast, Avaro Capital Advisors LLC trimmed its position by 190,405 shares, holding 5,959,595 shares valued at $97.4 million. State Street Corp also reduced its stake by 970,531 shares, now holding 2,260,512 shares valued at $36.96 million.

uniQure N.V. Stock Snapshot

Shares of uniQure N.V. (NasdaqGS: QURE) recently traded at $27.57. The company has a market cap of approximately $1.74 billion. With no meaningful P/E ratio due to its lack of profitability, the stock has a beta of 1.001. Over the past 52 weeks, the stock has ranged from a low of $8.73 to a high of $71.50. Its 50-day moving average is $22.49, and the 200-day moving average is $27.11. The company has a current ratio of 10.40 and a quick ratio of 9.97, indicating strong liquidity, although it carries a high debt-to-equity ratio of 365.37.

Recent Earnings

uniQure reported revenue of $18.1 million, with a revenue growth rate of 1.3%. However, the company posted a negative ROE of -228.24% and a net margin of 0.0%. Its next earnings report is scheduled for May 5, 2026.

Insider Buying and Selling at uniQure N.V.

Several insiders sold shares of uniQure on June 11, 2026, including Rachelle Suzanne Jacques, Robert Gut, Madhavan Balachandran, David Meek, Jeremy Springhorn, and Leonard Post. Each sold 1,993 shares at an average price of $27.06. Notably, Robert Gut's transaction was part of a pre-planned trading plan.

Analysts Set New Price Targets

On May 6, 2026, HC Wainwright & Co. maintained a 'buy' rating with a $50 price target. Earlier, Chardan Capital also maintained its 'buy' rating with a $37 target on April 30, 2026. Goldman Sachs held a 'hold' rating with a $10 target on April 20, 2026. The consensus among 11 analysts suggests a 'buy' rating with a mean price target of $38.96.

About uniQure N.V.

uniQure N.V., headquartered in Amsterdam, Netherlands, is a biotechnology company focused on developing treatments for rare and severe diseases. It offers HEMGENIX for hemophilia B and is advancing several gene therapy candidates, including AMT-130 for Huntington's disease and AMT-260 for epilepsy. With a workforce of 221 employees, uniQure is led by CEO Matthew Craig Kapusta.

Bottom Line

RTW Investments' decision to trim its stake in uniQure N.V. by over 1.1 million shares marks a notable change in its investment strategy. Investors often track such filings to gauge institutional sentiment, though it's important to remember that 13F filings are historical and may not reflect current positions. uniQure remains a company with active institutional interest and a diverse pipeline in the biotech sector.